Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis
Metrics: PDF 550 views | HTML 1061 views | ?
Ahrim Moon1,*, Sung-Im Do2,*, Hyun-Soo Kim3, Youn-Wha Kim4
1Department of Pathology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon-si, Gyeonggi-do, Republic of Korea
2Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
3Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
4Department of Pathology, Kyung Hee University School of Medicine, Seoul, Republic of Korea
*These authors have contributed equally to this work
Hyun-Soo Kim, email: email@example.com
Keywords: osteoprotegerin, downregulation, colorectal carcinoma, recurrent metastasis, immunohistochemistry
Received: August 25, 2016 Accepted: September 30, 2016 Published: October 15, 2016
We recently reported the downregulation of osteoprotegerin expression in primary colorectal carcinoma and its significant association with aggressive oncogenic behavior, which suggest that this process contributes to colorectal carcinoma development and progression. In this study, we used immunohistochemical staining to evaluate osteoprotegerin expression in 81 colorectal liver metastasis tissue samples and investigated its possible association with the clinicopathological characteristics and outcomes of patients with colorectal liver metastasis. These tissues exhibited significantly reduced expression of osteoprotegerin compared to primary colorectal carcinomas and normal colorectal mucosa. This reduced expression was significantly associated with the extent of colorectal liver metastasis, including multiplicity of metastatic tumors, involvement of the bilateral hepatic lobes, and higher histological grade. In addition, reduced osteoprotegerin expression was an independent significant predictor of recurrent liver metastasis and prognostic factor for reduced patient survival. These findings suggest that osteoprotegerin expression may be a novel predictor of recurrent liver metastasis and a prognostic biomarker in patients with colorectal liver metastasis. Patients harboring colorectal liver metastasis with reduced osteoprotegerin expression should be carefully monitored after hepatic resection for colorectal liver metastasis to enable early detection of potentially resectable metastatic recurrences.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.